Translating Research Into Practice (TRIP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03514433 |
Recruitment Status :
Completed
First Posted : May 2, 2018
Last Update Posted : September 28, 2023
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer, Breast | Other: TRIP Patient Navigation Intervention | Not Applicable |
This community-engaged program will demonstrate the feasibility of community-academic partnerships to provide innovations in information sharing and systems implementation targeted to reduce treatment disparities. Patient navigators will be able to utilize the patient database to track their patients throughout their treatment, and receive guidance regarding recommended social resources to patients experiencing hardships via the social determinants platform.
Who: The four Massachusetts CTSA hubs (Boston University, Harvard University, Tufts University, and University of Massachusetts) partnered with the Boston Breast Cancer Equity Coalition, and the 6 hospitals that care for women with breast cancer.
Patient population: about1,300 vulnerable inner city women with risk for delay in breast cancer care. Massachusetts (MA) Cancer Registry data identified the following characteristics of Boston residents with greatest delays in breast cancer treatment: Black, Hispanic, non-English speaking, and public health insurance. Six health care institutions care for >90% of these women:
- Beth Israel Deaconess Medical Center (site PI: Ted James, MD)
- Boston Medical Center (PI: Tracy Battaglia MD, MPH)
- Brigham Women's Hospital/Dana-Farber Cancer Institute (PI: Jennifer Haas MD, MPH)
- Faulkner Hospital (site PI: Rachel Freedman, MD)
- Massachusetts General Hospital (site PI: Beverly Moy, MD)
- Tufts Medical Center (PI: Karen Freund MD, MPH)
UMass Medical Center (PI: Stephenie Lemon, PhD) will play an integral role in the planning and implementation of the TRIP intervention but is not a clinical site.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1732 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | A randomized cluster stepped wedge design will be conducted. This pragmatic design involves a sequential, randomized roll-out of the intervention across 6 participating clinical sites or "clusters" over 3 month intervals or "steps". Consistent with a stepped wedge design with one cluster per step, prior to the collection of data in the pre-intervention period, the investigators will generate a set of uniform random numbers for each of the six clusters to assign a starting period for the study intervention. There will be no crossover of patients from usual care to the intervention. That is, patients at each site during the pre-intervention period will experience only usual care and will act as historical controls and those enrolled after the initiation of intervention will experience the intervention. |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Health Services Research |
Official Title: | Translating Research Into Practice: A Regional Collaborative to Reduce Disparities in Breast Cancer Care |
Actual Study Start Date : | August 6, 2018 |
Actual Primary Completion Date : | September 22, 2023 |
Actual Study Completion Date : | September 22, 2023 |
Arm | Intervention/treatment |
---|---|
No Intervention: Historical Control
This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
|
|
Experimental: TRIP Patient Navigation Intervention
This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
|
Other: TRIP Patient Navigation Intervention
The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services. |
- Time-to-treatment post-diagnosis [ Time Frame: Within 365 days of enrollment ]The receipt of care will be defined as initiation of care within 365 days. This will be a continuous outcome defined as the number of days from definitive tissue biopsy (Time 0) to treatment initiation (Time 1). Treatment initiation is defined as the date of first cancer treatment: surgical, radiation, or systemic therapy (including chemotherapy, immunotherapy, targeted therapy, hormonal therapy). Time to treatment initiation can take any value from 0 days to 365 days (study period). The clinical outcome will be derived from data in the patient's medical record.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | All women with breast cancer diagnosed at a participating study site during the study period will be eligible for inclusion if they meet three study criteria |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- are an adult female 18 years of age or older;
- reside within 25 miles of the City of Boston;
- have any of the following risk factors for delays in care: are Black and/or Hispanic ethnicity, do not speak English as their primary language, and/or have only public insurance or are uninsured at the time of diagnosis.
Exclusion Criteria:
- cancer diagnosis made > 60 days prior to enrollment, such that the ability of the intervention to effect the outcome is limited;
- presence of a cognitive impairment such as dementia or delirium from any cause (e.g. metabolic, medication or drug induced), given the unique challenges to their treatment decision making/ adherence and the fact that the intervention would not include the patient directly, but rather the family;
- home residence is outside of the city of Boston, Massachusetts.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514433
United States, Massachusetts | |
Tufts Medical Center | |
Boston, Massachusetts, United States, 02111 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Boston Medical Center | |
Boston, Massachusetts, United States, 02118 | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
Brigham and Women's Faulkner Hospital | |
Boston, Massachusetts, United States, 02215 | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | Tracy Battaglia, MD., MPH | Boston Medical Center |
Responsible Party: | Boston Medical Center |
ClinicalTrials.gov Identifier: | NCT03514433 |
Other Study ID Numbers: |
H-37314 1U01TR002070-01 ( U.S. NIH Grant/Contract ) |
First Posted: | May 2, 2018 Key Record Dates |
Last Update Posted: | September 28, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Patient Navigation Disparity Social Determinants |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |